234 related articles for article (PubMed ID: 22530037)
1. Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.
Bid HK; Oswald D; Li C; London CA; Lin J; Houghton PJ
PLoS One; 2012; 7(4):e35513. PubMed ID: 22530037
[TBL] [Abstract][Full Text] [Related]
2. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.
Onimoe GI; Liu A; Lin L; Wei CC; Schwartz EB; Bhasin D; Li C; Fuchs JR; Li PK; Houghton P; Termuhlen A; Gross T; Lin J
Invest New Drugs; 2012 Jun; 30(3):916-26. PubMed ID: 21340507
[TBL] [Abstract][Full Text] [Related]
3. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.
Zuo M; Li C; Lin J; Javle M
Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212
[TBL] [Abstract][Full Text] [Related]
4. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.
Couto JI; Bear MD; Lin J; Pennel M; Kulp SK; Kisseberth WC; London CA
BMC Vet Res; 2012 Dec; 8():244. PubMed ID: 23244668
[TBL] [Abstract][Full Text] [Related]
5. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.
Lin L; Benson DM; DeAngelis S; Bakan CE; Li PK; Li C; Lin J
Int J Cancer; 2012 Mar; 130(6):1459-69. PubMed ID: 21520044
[TBL] [Abstract][Full Text] [Related]
6. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer.
Chen J; Wang J; Lin L; He L; Wu Y; Zhang L; Yi Z; Chen Y; Pang X; Liu M
Mol Cancer Ther; 2012 Feb; 11(2):277-87. PubMed ID: 22203730
[TBL] [Abstract][Full Text] [Related]
8. The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.
Ball S; Li C; Li PK; Lin J
PLoS One; 2011 Apr; 6(4):e18820. PubMed ID: 21526200
[TBL] [Abstract][Full Text] [Related]
9. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
Zhang R; Chen X; Fu S; Xu L; Lin J
Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
[TBL] [Abstract][Full Text] [Related]
10. PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.
Huang SW; Lien JC; Kuo SC; Huang TF
Br J Pharmacol; 2014 Dec; 171(24):5728-42. PubMed ID: 25091695
[TBL] [Abstract][Full Text] [Related]
11. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
12. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.
Bid HK; Zhan J; Phelps DA; Kurmasheva RT; Houghton PJ
Mol Cancer Ther; 2012 Mar; 11(3):649-59. PubMed ID: 22188815
[TBL] [Abstract][Full Text] [Related]
14. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis.
Zhu BH; Zhan WH; Li ZR; Wang Z; He YL; Peng JS; Cai SR; Ma JP; Zhang CH
World J Gastroenterol; 2007 Feb; 13(8):1162-9. PubMed ID: 17451194
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
16. A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.
Tate CM; Mc Entire J; Pallini R; Vakana E; Wyss L; Blosser W; Ricci-Vitiani L; D'Alessandris QG; Morgante L; Giannetti S; Larocca LM; Todaro M; Benfante A; Colorito ML; Stassi G; De Maria R; Rowlinson S; Stancato L
PLoS One; 2015; 10(4):e0125697. PubMed ID: 25919028
[TBL] [Abstract][Full Text] [Related]
17. Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.
Wei CC; Ball S; Lin L; Liu A; Fuchs JR; Li PK; Li C; Lin J
Int J Oncol; 2011 Jan; 38(1):279-85. PubMed ID: 21109950
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells.
Lin L; Hutzen B; Lee HF; Peng Z; Wang W; Zhao C; Lin HJ; Sun D; Li PK; Li C; Korkaya H; Wicha MS; Lin J
PLoS One; 2013; 8(12):e82821. PubMed ID: 24376586
[TBL] [Abstract][Full Text] [Related]
19. The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth.
Bellou S; Karali E; Bagli E; Al-Maharik N; Morbidelli L; Ziche M; Adlercreutz H; Murphy C; Fotsis T
Mol Cancer; 2012 May; 11():35. PubMed ID: 22583931
[TBL] [Abstract][Full Text] [Related]
20. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]